Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (121-130 of 314) with videos related to

Pageof 32
Sort By:
Journal of Clinical Medicine|June 28, 2023
Building Team Medicine in the Management of CNS MetastasesArchit B Baskaran, Robin A Buerki, Osaama H Khan, et al.
Nature Reviews. Neurology|December 10, 2009
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Michael Weller, Roger Stupp, Guido Reifenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityMonika E Hegi, Lili Liu, James G Herman, et al.
Neuro-Oncology|October 26, 2012
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practiceMichael Weller, Roger Stupp, Monika E Hegi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE TrialsJulia Furtner, Michael Weller, Michael Weber, et al.
Cancer Treatment Reviews|January 6, 2017
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic reviewStephanie G C Kroeze, Corinna Fritz, Morten Hoyer, et al.
International Journal of Cancer|August 23, 2005
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapyKhalil Zaman, Robert Driscoll, Diane Hahn, et al.
Journal of Neuro-Oncology|February 10, 2018
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?Caroline Happold, Thierry Gorlia, L Burt Nabors, et al.
Ophthalmic Genetics|April 30, 2011
Chiasmatic infiltration secondary to late malignant transformation of retinomaAsimina Mataftsi, Leonidas Zografos, Aubin Balmer, et al.
The Oncologist|February 16, 2006
Changing paradigms--an update on the multidisciplinary management of malignant gliomaRoger Stupp, Monika E Hegi, Martin J van den Bent, et al.
Pageof 32

Showing results (121-130 of 314) with videos related to

Sort By:
Pageof 32
Journal of Clinical Medicine|June 28, 2023
Building Team Medicine in the Management of CNS MetastasesArchit B Baskaran, Robin A Buerki, Osaama H Khan, et al.
Nature Reviews. Neurology|December 10, 2009
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Michael Weller, Roger Stupp, Guido Reifenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityMonika E Hegi, Lili Liu, James G Herman, et al.
Neuro-Oncology|October 26, 2012
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practiceMichael Weller, Roger Stupp, Monika E Hegi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE TrialsJulia Furtner, Michael Weller, Michael Weber, et al.
Cancer Treatment Reviews|January 6, 2017
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic reviewStephanie G C Kroeze, Corinna Fritz, Morten Hoyer, et al.
International Journal of Cancer|August 23, 2005
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapyKhalil Zaman, Robert Driscoll, Diane Hahn, et al.
Journal of Neuro-Oncology|February 10, 2018
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?Caroline Happold, Thierry Gorlia, L Burt Nabors, et al.
Ophthalmic Genetics|April 30, 2011
Chiasmatic infiltration secondary to late malignant transformation of retinomaAsimina Mataftsi, Leonidas Zografos, Aubin Balmer, et al.
The Oncologist|February 16, 2006
Changing paradigms--an update on the multidisciplinary management of malignant gliomaRoger Stupp, Monika E Hegi, Martin J van den Bent, et al.
Pageof 32